Cryptic Resistance Mutations Associated With Misdiagnoses of Multidrug-Resistant Tuberculosis

J Infect Dis. 2019 Jun 19;220(2):316-320. doi: 10.1093/infdis/jiz104.

Abstract

Understanding why some multidrug-resistant tuberculosis cases are not detected by rapid phenotypic and genotypic routine clinical tests is essential to improve diagnostic assays and advance toward personalized tuberculosis treatment. Here, we combine whole-genome sequencing with single-colony phenotyping to identify a multidrug-resistant strain that had infected a patient for 9 years. Our investigation revealed the failure of rapid testing and genome-based prediction tools to identify the multidrug-resistant strain. The false-negative findings were caused by uncommon rifampicin and isoniazid resistance mutations. Although whole-genome sequencing data helped to personalize treatment, the patient developed extensively drug-resistant tuberculosis, highlighting the importance of coupling new diagnostic methods with appropriate treatment regimens.

Keywords: Tuberculosis; cryptic mutations; drug resistance; individualized treatment; whole-genome sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Bacterial Proteins / genetics
  • Diagnostic Errors / prevention & control
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Extensively Drug-Resistant Tuberculosis / drug therapy
  • Extensively Drug-Resistant Tuberculosis / genetics*
  • Genome, Bacterial / genetics
  • Genotype
  • Humans
  • Isoniazid / therapeutic use
  • Microbial Sensitivity Tests / methods
  • Mutation / genetics*
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / genetics*
  • Rifampin / therapeutic use
  • Sequence Analysis, DNA / methods
  • Tuberculosis, Multidrug-Resistant / genetics*
  • Whole Genome Sequencing / methods

Substances

  • Antitubercular Agents
  • Bacterial Proteins
  • Isoniazid
  • Rifampin